Biopharmaceutical company EyePoint Pharmaceuticals has entered into a partnership with supply group purchasing organization Vizient to offer its postoperative inflammation drug dexycu to Vizient's customers.
The partnership began Nov. 1. Vizient customers, which includes 50 percent of acute care providers and 20 percent of ambulatory providers, will receive the drug at a discount. The partnership is slated to last three years.
"Since the launch of dexycu in the first quarter of this year, EyePoint’s dedicated sales team has been making consistent headway in penetrating targeted ambulatory surgical centers to deliver Dexycu to patients who can benefit from the product’s differentiated profile and efficacy," said Nancy Lurker, president and CEO of EyePoint Pharmaceuticals.